Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
Here is how Atossa Genetics Inc. (ATOS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Atossa Genetics (ATOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Atossa Therapeutics, Inc. (NASDAQ:ATOS ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Michael Parks - VP of Investor and Public Relations Steven Quay - President and CEO Heather Rees - CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good morning, everyone, and welcome to the Atossa Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call.
Here is how Atossa Genetics Inc. (ATOS) and Gilead Sciences (GILD) have performed compared to their sector so far this year.
Here is how Atossa Genetics Inc. (ATOS) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Here is how Atossa Genetics Inc. (ATOS) and CorMedix (CRMD) have performed compared to their sector so far this year.
Here is how Atossa Genetics Inc. (ATOS) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.
Does Atossa Genetics Inc. (ATOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Atossa Genetics Inc. (ATOS) and Hologic (HOLX) have performed compared to their sector so far this year.
By now, you're well aware of the dangers of trading penny stocks with upside. But as a reminder, not only will you find a disclaimer at the tail-end of this article about penny stock dangers, but here's what the U.S. SEC says: “ Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you have them.